Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma

Molecular and Cellular Biology

Volumn 23, Issue 2, 2003, Pages 482-492

  Eliazer, Susan ^a   Spencer, Jeffrey ^a   Ye, Dan ^a   Olson, Eric ^a   Ilaria Jr , Robert L ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CYCLIN D1; FAT; MYOGENIC FACTOR; MYOGENIN; PROTEIN; PROTEIN FLI1; PROTEIN P21; RNA BINDING PROTEIN EWS; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE; CANCER CELL CULTURE; CELL DENSITY; CELL DIFFERENTIATION; CHIMERA; CONTROLLED STUDY; DNA BINDING; EWING SARCOMA; GENE EXPRESSION; GENE FUSION; GENETIC TRANSCRIPTION; HISTOCHEMISTRY; MESODERM; MUSCLE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALKALINE PHOSPHATASE; ANIMALS; BLOTTING, WESTERN; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE; CELL LINEAGE; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FLOW CYTOMETRY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MICE; MICROSCOPY, FLUORESCENCE; MODELS, BIOLOGICAL; MYOD PROTEIN; MYOGENIN; ONCOGENE PROTEINS, FUSION; ONCOGENES; PLASMIDS; PROTO-ONCOGENE PROTEIN C-FLI-1; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, EWING'S; SIGNAL TRANSDUCTION; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION;

ANIMALIA; MURINAE;

EID: 0037218795     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.23.2.482-492.2003     Document Type: Article

References (56)

1. Arvand, A., and C. T. Denny. 2001. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20:5747-5754.
2. Bailly, R. A., R. Bosselut, J. Zucman, F. Cormier, O. Delattre, M. Roussel, G. Thomas, and J. Ghysdael. 1994. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11; 22) translocation in Ewing sarcoma. Mol. Cell. Biol. 14:3230-3241.
3. Bennett, A. M., and N. K. Tonks. 1997. Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science 278:1288-1291.
4. Braun, T., E. Bober, G. Buschhausen-Denker, S. Kohtz, K. H. Grzeschik, H. H. Arnold, and S. Kotz. 1989. Differential expression of myogenic determination genes in muscle cells: Possible autoactivation by the Myf gene products. EMBO J. 8:3617-3625.
5. Buckingham, M. 2001. Skeletal muscle formation in vertebrates. Curr. Opin. Genet. Dev. 11:440-448.
6. Cheng, T. C., T. A. Hanley, J. Mudd, J. P. Merlie, and E. N. Olson. 1992. Mapping of myogenin transcription during embryogenesis using transgenes linked to the myogenin control region. J. Cell Biol. 119:1649-1656.
7. Cheng, T. C., M. C. Wallace, J. P. Merlie, and E. N. Olson. 1993. Separable regulatory elements governing myogenin transcription in mouse embryogenesis. Science 261:215-218.
8. Cuenda, A., and P. Cohen. 1999. Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J. Biol. Chem. 274:4341-4346.
9. Dauphinot, L., C. De Oliveira, T. Melot, N. Sevenet, V. Thomas, B. E. Weissman, and O. Delattre. 2001. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 20:3258-3265.
10. Ducy, P., M. Starbuck, M. Priemel, J. Shen, G. Pinero, V. Geoffroy, M. Amling, and G. Karsenty. 1999. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 13:1025-1036.
11. Edmondson, D. G., T. C. Cheng, P. Cserjesi, T. Chakraborty, and E. N. Olson. 1992. Analysis of the myogenin promoter reveals an indirect pathway for positive autoregulation mediated by the muscle-specific enhancer factor MEF-2. Mol. Cell. Biol. 12:3665-3677.
12. Fechner, R. E., and S. E. Mills. 1993. Small cell sarcomas, p. 187-201. In J. Rosai (ed.), The Atlas of Tumor Pathology, 3rd Series, Vol. 8. Tumors of the Bones and Joints. Armed Forces Institute of Pathology, Washington, D.C.
13. Franchi, A., G. Pasquinelli, G. Cenacchi, C. Della Rocca, C. Gambini, M. Bisceglia, G. N. Martinelli, and M. Santucci. 2001. Immunohistochemical and ultrastructural investigation of neural differentiation in Ewing sarcoma/PNET of bone and soft tissues. Ultrastruct. Pathol. 25:219-225.
14. Franke, T. F., S. I. Yang, T. O. Chan, K. Datta, A. Kazlauskas, D. K. Morrison, D. R. Kaplan, and P. N. Tsichlis. 1995. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81:727-736.
15. Grigoriadis, A. E., J. N. Heersche, and J. E. Aubin. 1988. Differentiation of muscle, fat, cartilage, and bone from progenitor cells present in a bone-derived clonal cell population: Effect of dexamethasone. J. Cell Biol. 106: 2139-2151.
16. Guo, K., J. Wang, V. Andres, R. C. Smith, and K. Walsh. 1995. MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol. Cell. Biol. 15:3823-3829.
17. Halevy, O., B. G. Novitch, D. B. Spicer, S. X. Skapek, J. Rhee, G. J. Hannon, D. Beach, and A. B. Lassar. 1995. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018-1021.
18. Hawley, R. G., F. H. Lieu, A. Z. Fong, and T. S. Hawley. 1994. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1:136-138.
19. Jiang, B. H., M. Aoki, J. Z. Zheng, J. Li, and P. K. Vogt. 1999. Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. Proc. Natl. Acad. Sci. USA 96:2077-2081.
20. Jiang, B. H., J. Z. Zheng, and P. K. Vogt. 1998. An essential role of phosphatidylinositol 3-kinase in myogenic differentiation. Proc. Natl. Acad. Sci. USA 95:14179-14183.
21. Kaliman, P., F. Vinals, X. Testar, M. Palacin, and A. Zorzano. 1996. Phosphatidylinositol 3-kinase inhibitors block differentiation of skeletal muscle cells. J. Biol. Chem. 271:19146-19151.
22. Katagiri, T., S. Akiyama, M. Namiki, M. Komaki, A. Yamaguchi, V. Rosen, J. M. Wozney, A. Fujisawa-Sehara, and T. Suda. 1997. Bone morphogenetic protein-2 inhibits terminal differentiation of myogenic cells by suppressing the transcriptional activity of MyoD and myogenin. Exp. Cell Res. 230:342-351.
23. Katagiri, T., A. Yamaguchi, M. Komaki, E. Abe, N. Takahashi, T. Ikeda, V. Rosen, J. M. Wozney, A. Fujisawa-Sehara, and T. Suda. 1994. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127:1755-1766.
24. Lassar, A. B., M. J. Thayer, R. W. Overell, and H. Weintraub. 1989. Transformation by activated ras or fos prevents myogenesis by inhibiting expression of MyoD1. Cell 58:659-667.
25. Lawlor, E. R., C. Scheel, J. Irving, and P. H. Sorensen. 2002. Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors. Oncogene 21:307-318.
26. Llombart-Bosch, A., A. Peydro-Olaya, and F. Gomar. 1980. Ultrastructure of one Ewing's sarcoma of bone with endothelial character and a comparative review of the vessels in 27 cases of typical Ewing's sarcoma. Pathol. Res. Pract. 167:71-87.
27. Maitra, A., H. Roberts, A. G. Weinberg, and J. Geradts. 2001. Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. Arch. Pathol. Lab. Med. 125:1207-1212.
28. Malaval, L., F. Liu, P. Roche, and J. E. Aubin. 1999. Kinetics of osteoprogenitor proliferation and osteoblast differentiation in vitro. J. Cell. Biochem. 74:616-627.
29. Marsh, M. E., A. M. Munne, J. J. Vogel, Y. Cui, and R. T. Franceschi. 1995. Mineralization of bone-like extracellular matrix in the absence of functional osteoblasts. J. Bone Miner. Res. 10:1635-1643.
30. Matsumoto, Y., K. Tanaka, F. Nakatani, T. Matsunobu, S. Matsuda, and Y. Iwamoto. 2001. Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1)regulatory genes. Br. J. Cancer 84:768-775.
31. May, W. A., S. L. Lessnick, B. S. Braun, M. Klemsz, B. C. Lewis, L. B. Lunsford, R. Hromas, and C. T. Denny. 1993. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol. Cell. Biol. 13:7393-7398.
32. Ohno, T., M. Ouchida, L. Lee, Z. Gatalica, V. N. Rao, and E. S. Reddy. 1994. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 9:3087-3097.
33. Olson, E. N., G. Spizz, and M. A. Tainsky. 1987. The oncogenic forms of N-ras or H-ras prevent skeletal myoblast differentiation, Mol. Cell. Biol. 7:2104-2111.
34. Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90:8392-8396.
35. Perry, R. L., M. H. Parker, and M. A. Rudnicki. 2001. Activated MEK1 binds the nuclear MyoD transcriptional complex to repress transactivation. Mol. Cell 8:291-301.
36. Povysil, C., and Z. Matejovsky. 1977. Ultrastructure of Ewing's tumour. Virchows Arch. A 374:303-316.
37. Puri, P. L., Z. Wu, P. Zhang, L. D. Wood, K. S. Bhakta, J. Han, J. R. Feramisco, M. Karin, and J. Y. Wang. 2000. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev. 14:574-584.
38. Ramocki, M. B., S. E. Johnson, M. A. White, C. L. Ashendel, S. F. Konieczny, and E. J. Taparowsky. 1997. Signaling through mitogen-activated protein kinase and Rac/Rho does not duplicate the effects of activated Ras on skeletal myogenesis. Mol. Cell. Biol. 17:3547-3555.
39. Rao, S. S., C. Chu, and D. S. Kohtz. 1994. Ectopic expression of cyclin D1 prevents activation of gene transcription by myogenic basic helix-loop-helix regulators. Mol. Cell. Biol. 14:5259-5267.
40. Sherr, C. J., and J. M. Roberts. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13:1501-1512.
41. Shimokawa, T., M. Kato, O. Ezaki, and S. Hashimoto. 1998. Transcriptional regulation of muscle-specific genes during myoblast differentiation. Biochem. Biophys. Res. Commun. 246:287-292.
42. Silvany, R. E., S. Eliazer, N. C. Wolff, and R. L. Ilaria, Jr. 2000. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene 19:4523-4530.
43. Skapek, S. X., J. Rhee, D. B. Spicer, and A. B. Lassar. 1995. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267:1022-1024.
44. Sorensen, P. H., H. Shimada, X. F. Liu, J. F. Lim, G. Thomas, and T. J. Triche. 1995. Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI-1 fusion gene. Cancer Res. 55: 1385-1392.
45. Spencer, J. A., S. Eliazer, R. L. Ilaria, Jr., J. A. Richardson, and E. N. Olson. 2000. Regulation of microtubule dynamics and myogenic differentiation by MURF, a striated muscle RING-finger protein. J. Cell Biol. 150:771-784.
46. Takasaki, Y., J. S. Deng, and E. M. Tan. 1981. A nuclear antigen associated with cell proliferation and blast transformation. J. Exp. Med. 154:1899-1909.
47. Teboul, L., D. Gaillard, L. Staccini, H. Inadera, E. Z. Amri, and P. A. Grimaldi. 1995. Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells. J. Biol. Chem. 270:28183-28187.
48. Thayer, M. J., S. J. Tapscott, R. L. Davis, W. E. Wright, A. B. Lassar, and H. Weintraub. 1989. Positive autoregulation of the myogenic determination gene MyoD1. Cell 58:241-248.
49. Toretsky, J. A., M. Thakar, A. E. Eskenazi, and C. N. Frantz. 1999. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Res. 59:5745-5750.
50. Valdez, M. R., J. A. Richardson, W. H. Klein, and E. N. Olson. 2000. Failure of Myf5 to support myogenic differentiation without myogenin. MyoD, and MRF4. Dev. Biol. 219:287-298.
51. Waga, S., G. J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578.
52. Wang, J., and K. Walsh. 1996. Inhibition of retinoblastoma protein phosphorylation by myogenesis-induced changes in the subunit composition of the cyclin-dependent kinase 4 complex. Cell Growth Differ. 7:1471-1478.
53. Wang, N. P., J. Marx, M. A. McNutt, J. C. Rutledge, and A. M. Gown. 1995. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood. Am. J. Pathol. 147:1799-1810.
54. Yaffe, D., and O. Saxel. 1977. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270:725-727.
55. Yamaguchi, A., T. Katagiri, T. Ikeda, J. M. Wozney, V. Rosen, E. A. Wang, A. J. Kahn, T. Suda, and S. Yoshiki. 1991. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J. Cell Biol. 113:681-687.
56. Zetser, A., E. Gredinger, and E. Bengal. 1999. p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor. J. Biol. Chem. 274:5193-5200.